Abstract
The Austrian Breast Cancer Group (ABC) consisting of more than 60 participating centers in Austria has randomized more than 5800 patients in 11 randomized trials since 1984. At present, roughly 30% of all patients with the diagnosis primary breast cancer are accrued in protocols throughout the country. Due to specific activities, the breast conservation rate raised from an initial 20% to more than 60% in the last years. Multicenter trials are not only the basis for progress in medicine but also tools for quality control and quality improvement.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Österreich
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Combined Modality Therapy
-
Female
-
Humans
-
Mastectomy, Segmental
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / mortality
-
Neoplasms, Hormone-Dependent / surgery
-
Randomized Controlled Trials as Topic
-
Survival Rate
Substances
-
Antineoplastic Agents, Hormonal